Status:
COMPLETED
Anti-angiogenesis Agent AG-013736 in Patients With Advanced Non-Small Cell Lung Cancer
Lead Sponsor:
Pfizer
Conditions:
Lung Neoplasms
Carcinoma, Non-small Cell Lung
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This is a Phase 2 study being conducted at multiple centers in the United States and Germany. Patients having non-small cell lung cancer that has spread to other parts of the body (i.e., metastatic) o...
Eligibility Criteria
Inclusion
- Histologically documented non-small cell lung cancer with metastases (Stage IV or recurrent disease) or locally advanced (Stage IIIB) with malignant pleural effusion.
- At least 1 prior systemic therapy for metastatic disease (Prior adjuvant therapy for localized disease does not count as a prior therapy for metastatic disease).
Exclusion
- Central lung lesions involving major blood vessels (arteries or veins). (Central lesions that maintain the structural integrity of vessels have the potential to bleed if the tumor lesion undergoes necrosis. MRI or CT angiography should be used in any case where there is any question as to whether blood vessels are involved.)
- Patients with a history of Grade 2 or worse hemoptysis are not eligible. Patients with a history of Grade 1 hemoptysis within 30 days of entry are not eligible
Key Trial Info
Start Date :
February 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2007
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT00094094
Start Date
February 1 2005
End Date
July 1 2007
Last Update
June 26 2012
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Irvine, California, United States, 92612
2
Pfizer Investigational Site
Orange, California, United States, 92868
3
Pfizer Investigational Site
Chicago, Illinois, United States, 60637
4
Pfizer Investigational Site
Park Ridge, Illinois, United States, 60068